Henry Ford declines further comment on Dr. Fauci's assessment of 'flawed' hydroxychloroquine study


  • Shutterstock

Henry Ford Health System released a statement in response to Dr. Anthony Fauci, who last week said its study of hydroxychloroquine, a controversial drug touted by President Donald Trump as a possible COVID-19 cure, was "flawed."

In an open letter posted on its website on Saturday, two of the health system's executives said that while the study was not randomized and double-blind — considered the "gold standard" of scientific studies — they supported its release due to the fact that it could be executed more quickly.

"Our goal as scientists has solely been to report validated findings and allow the science to speak for itself, regardless of political considerations," they wrote.

But when they released the study, President Donald Trump immediately seized upon the results for political gain.

"The highly respected Henry Ford Health System just reported, based on a large sampling, that HYDROXYCHLOROQUINE cut the death rate in certain sick patients very significantly," he tweeted. "The Dems disparaged it for political reasons (me!). Disgraceful."

The study soon went viral, with Trump's supporters accusing the mainstream media of suppressing knowledge of the drug to spite Trump.

"Unfortunately, the political climate that has persisted has made any objective discussion about this drug impossible, and we are deeply saddened by this turn of events," the Health System said — which is a bit of a curious statement considering that the drug had become a political football before the study even started.

The Health System is declining further comment. While it is also working on a randomized, double-blind study of the drug as a preventive measure, it has not yet released those results.

You can read the full open letter below:

To our friends and colleagues around the country and globe:

We believe wholeheartedly that a mission statement is more than a plaque we hang on a wall, but rather an idea we embed in our hearts and minds that unifies, empowers and enables us to do what we do every day for the people of our communities.

Our mission is to improve people’s lives through excellence in the science and art of health care and healing. For more than 100 years, we have proudly pioneered clinical and scientific breakthroughs that have advanced health care here and abroad.

As an early hotspot for the COVID-19 pandemic, we have seen and lived its devastating effects alongside our patients and families. Perhaps that’s what makes us even more determined to rally our researchers, frontline care team members and leaders together in boldness, participating in scientific research, including clinical trials, to find the safest care and most effective treatments. While feeling the same sense of urgency everyone else does to recognize a simple, single remedy for COVID-19, we need to be realistic in the time it takes to fully understand the optimal therapy or combination of therapies required of a new virus we are all trying to contain.

The most well-accepted and definitive method to determine the efficacy of a treatment is a double-blind, randomized clinical trial. However, this type of study takes a long time to design, execute and analyze. Therefore, a whole scientific field exists in which scientists examine how a drug is working in the real world to get as best an answer as they can as soon as possible. These types of studies can be done much more rapidly with data that is already available, usually from medical records.

Like all observational research, these studies are very difficult to analyze and can never completely account for the biases inherent in how doctors make different decisions to treat different patients. Furthermore, it is not unusual that results from such studies vary in different populations and at different times, and no one study can ever be considered all by itself.

Our promising Henry Ford treatment study should be considered as another important contribution to the other studies of hydroxychloroquine that describes what the authors found in our patient population. We – along with all doctors and scientists – eagerly support the need for randomized clinical trials.

We also want to point out that scientific debate is a common occurrence with almost every published study. In part, this is what fuels the advancement of knowledge – challenging one another on our assumptions, conclusions and applications to get to a better place for the patients we collectively serve. You can read the original study here and the senior author’s letter to the editor here.

Unfortunately, the political climate that has persisted has made any objective discussion about this drug impossible, and we are deeply saddened by this turn of events. Our goal as scientists has solely been to report validated findings and allow the science to speak for itself, regardless of political considerations. To that end, we have made the heartfelt decision to have no further comment about this outside the medical community – staying focused on our core mission in the interest of our patients, our community, and our commitment to clinical and academic integrity.

Thank you for your support.


Adnan Munkarah, M.D., Executive Vice President and Chief Clinical Officer
Steven Kalkanis, M.D., Senior Vice President and Chief Academic Officer

Stay on top of Detroit news and views. Sign up for our weekly issue newsletter delivered each Wednesday.

We welcome readers to submit letters regarding articles and content in Detroit Metro Times. Letters should be a minimum of 150 words, refer to content that has appeared on Detroit Metro Times, and must include the writer's full name, address, and phone number for verification purposes. No attachments will be considered. Writers of letters selected for publication will be notified via email. Letters may be edited and shortened for space.

Email us at letters@metrotimes.com.

Support Local Journalism.
Join the Detroit Metro Times Press Club

Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.

Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.

Join the Metro Times Press Club for as little as $5 a month.